@phdthesis{oai:kagawa-u.repo.nii.ac.jp:00011466,
 author = {籏智, 幸政 and Hatachi, Yukimasa},
 month = {2022-10-18, 2022-10-18, 2022-10-18},
 note = {Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use., Patients and methods: Patients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities., Results: Patients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months., Conclusion: The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , l-leucovorin 400 mg/m 2 and 5-FU 2,400 mg/m 2 , administered as a continuous 46-h infusion.},
 school = {香川大学, Kagawa University},
 title = {FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)},
 year = {},
 yomi = {ハタチ, ユキマサ}
}